ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

July 30, 2004

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

Clearinghouse Finds Five Compounds Pose Risk To Humans

March 2, 1979

NCI Gets Concept Approval for New Communications Network

May 27, 1988

A Provision Of The EARLY Bill Is Inserted Into House Appropriations For Labor, HHS

July 24, 2009

Clinical Trials Approved By NCI CTEP Last Month

April 29, 2011